Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Model structure
The population is divided into the following four classes: susceptible, exposed (and not yet symptomatic), infectious (and symptomatic), and removed (ie, isolated, recovered, or otherwise non-infectious). A fraction of exposed individuals subsequently travel and are eventually detected in their destination country.
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Characteristics of the studies included in the quantitative analysis
Study | Country | Design | P (patients) | I (intervention) | C (comparator) | O (outcome) |
---|---|---|---|---|---|---|
Khan [29 (link)] | Bangladesh | Retrospective, cohort | PCR confirmed COVID-19 patients (n = 248) | 12-mg ivermectin (single dose) plus standard care | Standard care (as required and included antipyretics for fever, anti-histamines for cough, and antibiotics to control secondary infection) | - Time required for virological clearance - Disease progression (develop pneumonia to severe respiratory distress) - Duration of hospital stays, and - Mortality rate |
Ahmed [28 (link)] | Bangladesh | double-blinded randomized controlled trial | Hospitalized COVID-19 patients (n = 72) | Group A: 12-mg ivermectin daily for 5 days | Group B: 12-mg ivermectin and 200-mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days) Group C: placebo | Primary endpoints: - Time required for virological clearance - Remission of fever and cough within 7 days Secondary outcomes: - Failure to maintain an SpO2 > 93% despite oxygenation - Days on oxygen support - The duration of hospitalization - All-cause mortality |
Babalola [27 (link)] | Nigeria | double-blinded randomized controlled trial | PCR-proven COVID-19 positive patients (n = 62) | Group A: Standard care plus ivermectin 6 mg every 84 h, twice a week, for 2 weeks Group B: Standard care plus ivermectin 12 mg every 84 h, twice a week, for 2 weeks | Group C: Standard care plus lopinavir/ritonavir daily for 2 weeks | - Time required for virological clearance |